Pictet Asset Management’s ImmunityBio IBRX Stock Holding History

Pictet Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.43M	Buy	847,659 +17,522	+2%	+$133K	0.01%	736
2026 Q1	$5.59M	Buy	830,137 +796,470	+2,366%	+$5.45M	0.01%	764
2025 Q4	$66.7K	Hold	33,667	–	–	﹤0.01%	2055
2025 Q3	$82.8K	Hold	33,667	–	–	﹤0.01%	1998
2025 Q2	$88.9K	Buy	33,667 +12,111	+56%	+$32.6K	﹤0.01%	1958
2025 Q1	$64.9K	Hold	21,556	–	–	﹤0.01%	1979
2024 Q4	$55.2K	Hold	21,556	–	–	﹤0.01%	2014
2024 Q3	$80.2K	Hold	21,556	–	–	﹤0.01%	1969
2024 Q2	$136K	Hold	21,556	–	–	﹤0.01%	1844
2024 Q1	$116K	Hold	21,556	–	–	﹤0.01%	1861
2023 Q4	$108K	Hold	21,556	–	–	﹤0.01%	1865
2023 Q3	$36.4K	Buy	+21,556	New	+$43.3K	﹤0.01%	1924

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pictet Asset Management's IBRX Position: Q2 2026 in Review

Pictet Asset Management increased its ImmunityBio (IBRX) stake by 2.1% in Q2 2026, buying an estimated $133K and bringing the position to 847,659 shares worth $7.43M. The position accounts for 0.01% of the portfolio, ranked #736.

Pictet Asset Management first reported a position in IBRX in Q3 2023 and has held it in 12 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Pictet Asset Management held 847,659 shares of ImmunityBio worth $7.43M as of Q2 2026.
Pictet Asset Management bought 17,522 ImmunityBio shares in Q2 2026, an estimated $133K.
ImmunityBio made up 0.01% of Pictet Asset Management's portfolio in Q2 2026, its #736 holding.
Pictet Asset Management first reported a position in ImmunityBio in Q3 2023 and has held it in 12 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.